Articles dans des revues avec comité de lecture (396)
  1. 121. Kourie Hampig, R., & Awada, A. (2015). Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers? Future oncology, 11(22), 3053-3055. doi:10.2217/fon.15.187
  2. 122. Venugopal, B., Awada, A., Evans, T. R. J., Dueland, S., Hendlisz, A., Rasch, W., Hernes, K., Hagen, S., & Aamdal, S. (2015). A first-in-human phase i and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer chemotherapy and pharmacology, 76(4), 785-792. doi:10.1007/s00280-015-2846-0
  3. 123. Awada, A., Munzert, G., Pilz, K., Liu, D., Schöffski, P., Dumez, H., Aftimos, P., Costermans, J., Bartholomeus, S., Forceville, K., Berghmans, T., Meeus, M. A., & Cescutti, J. (2015). Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: Safety, pharmacokinetics and activity. Investigational new drugs, 33(3), 611-620. doi:10.1007/s10637-015-0223-9
  4. 124. El Hajj, P., Gilot, D., Migault, M., Theunis, A., van Kempen, L., Sales, F., Fayyad Kazan, H., Badran, B., Larsimont, D., Awada, A., Bachelot, L., Galibert, M. D., Ghanem, G. E., & Journé, F. (2015). SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma. British Journal of Cancer, 113(1), 91-98. doi:10.1038/bjc.2015.194
  5. 125. Barthélémy, P., Aftimos, P., & Awada, A. (2015). New generations of targeted therapies fighting the resistance in solid tumors. Current opinion in oncology, 27(3), 243-249. doi:10.1097/CCO.0000000000000175
  6. 126. Kotecki, N., Penel, N., & Awada, A. (2015). Metabolic disorders associated with the use of targeted cancer therapies. Current opinion in oncology, 27(3), 258-266. doi:10.1097/CCO.0000000000000176
  7. 127. Gombos, A., Barthélémy, P., & Awada, A. (2015). Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer. Expert Opinion on Drug Metabolism & Toxicology, 11(5), 823-834. doi:10.1517/17425255.2015.1013464
  8. 128. Hendlisz, A., Golfinopoulos, V., Deleporte, A., Mansy, H. E., Vandeputte, C., Maetens, M. M., Awada, A., Piccart-Gebhart, M., Paesmans, M., Garcia, C., Flamen, P., Peeters, M., Annemans, L., Van Den Eynde, M., Borbath, I., Dresse, D., Houbiers, G., Fried, M., Marechal, R., & Van Laethem, J.-L. (2015). Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study [BMC Cancer, 13, (2013), 190]. BMC cancer, 15(1), 173. doi:10.1186/s12885-015-1181-5
  9. 129. Kaufman, P. P., Perez, E. A., Olivo, M., He, Y., Dutcus, C. C., Awada, A., Twelves, C., Velikova, G., Yelle, L., & Cortes, J. (2015). Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of clinical oncology, 33(6), 594-601. doi:10.1200/JCO.2013.52.4892
  10. 130. Twelves, C., Cortes, J., Vahdat, L. L., Olivo, M., He, Y., Kaufman, P. P., & Awada, A. (2015). Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies[ Breast Cancer Res Treat (2014), 148, 553-561, DOI 10.1007/s10549-014-3144-y]. Breast cancer research and treatment, 149(1), 313. doi:10.1007/s10549-014-3245-7
  11. 131. Awada, G., Kourie Hampig, R., & Awada, A. (2015). Novel mechanisms and approaches in the medical therapy of solid cancers. Discovery medicine, 20(108), 33-41.
  12. 132. Perez, E. A., Yardley, D., Potter, D. D., Mailliez, A., Moreno-Aspitia, A., Ahn, J. S., Zhao, C., Hoch, U., Tagliaferri, M., Hannah, A. L., Cortes, J., Awada, A., O'Shaughnessy, J., Rugo, H., Twelves, C., Im, S. A., Gómez-Pardo, P., Schwartzberg, L. L., & Diéras, V. (2015). Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial. Lancet oncology, 16(15), 1556-1568. doi:10.1016/S1470-2045(15)00332-0
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>